-
Company Profile
Soligenix Inc – Company Profile
Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis, mild to moderate psoriasis, and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active...
Add to Basket -
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07328948 in Diastolic Heart Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PF-07328948 in Diastolic Heart FailureDrug Details: PF-07328948 is under development for the treatment of an heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAY-2965501 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BAY-2965501 in Solid Tumor Drug Details: BAY-2965501 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hypericin Sodium in Mycosis Fungoides
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Hypericin Sodium in Mycosis FungoidesDrug Details:Hypericin (SGX-301, HBP-347) is under development for the treatment of cutaneous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-57643 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INCB-57643 in Myelodysplastic Syndrome Drug Details:INCB-57643 is under development for the treatment of refractory primary myelofibrosis,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiVax in Poisoning
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RiVax in PoisoningDrug Details:RiVax is under development to protect against exposure to ricin toxin poisoning. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Non-Small Cell Lung Cancer Drug Details:IOA-244 is under development for the treatment of solid...
-
Product Insights
Mycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Mycosis Fungoides Clinical Trials Market Report Overview The Mycosis Fungoides clinical trial market research report provides an overview of the Mycosis Fungoides clinical trials scenario. The report provides top-line data relating to the clinical trials on Mycosis Fungoides. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Net Present Value Model: HyBryte
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model HyBryte Drug Details Hypericin (SGX-301, HBP-347)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SGX-201
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SGX-201 Drug Details SGX-201 (delayed release beclomethasone 17,21-dipropionate) is under development for the prevention...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – beclomethasone dipropionate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry beclomethasone dipropionate Drug Details SGX-203 (beclomethasone 17,21-dipropionate or BDP) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – hypericin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry hypericin Drug Details Hypericin (SGX-301, HBP-347) is under development for the treatment of mild-moderate...
-
Product Insights
Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia. The Burkholderia Pseudomallei Infections (Melioidosis) pipeline drugs market research report provides a comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development,...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape. Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome...
-
Product Insights
Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared-up skin, itchiness, burning sensation, and swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections, and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. The Psoriasis pipeline market research report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug...
-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Marburgvirus Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Marburgvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburgvirus Infections and features dormant...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Ebolavirus Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Ebolavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections and features dormant...
-
Product Insights
Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Crohn’s Disease (Regional Enteritis) pipeline market research report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease...